glp 1 powerpoint presentation PPT - Improved Cardiovascular Health with GLP-1 Agonists Graphical presentation of the mechanism

19 This discrepancy highlights the gap between efficacy observed in controlled trial settings and effectiveness in routine clinical practice

This combination of increased usage and expanded state coverage has increased Medicaid spending on GLP-1s for obesity to more than $500 million in October 2024 alone, with total expenditures reaching $3.5 billion over the past 12 months

For more information on GLP-1 agonists, check out Anesthesia Updates on the NYSORA Anesthesia Manual App

GLP-1RAs have transformed type 2 diabetes (T2D) treatment, offering not only robust glycemic control but also CV protection (48)

Always consult your healthcare provider before starting treatment

Then they must meet the clinical criteria and commit to lifestyle modifications